Does Enteral Aspirin (75 mg Once Daily) Improve Surrogate Outcomes in Adults With ARDS?

**STUDY DESIGN**

- Randomized, double-blinded, placebo-controlled trial of patients with ARDS by Berlin definition in 5 UK ICUs
- Patients recruited from February 10, 2015, to November 25, 2018
- Primary outcome was oxygenation index at day 7
- Trial stopped early after 49 of a planned 60 patients due to slow recruitment

**RESULTS**

<table>
<thead>
<tr>
<th></th>
<th>Oxygenation Index (mean + SD)</th>
<th>Aspirin (n = 24)</th>
<th>Placebo (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>54 ± 27</strong></td>
<td></td>
<td>54 ± 27</td>
<td>42 ± 25</td>
</tr>
</tbody>
</table>

No difference in adverse events between the groups (OR 1.04; 95% CI, 0.56-1.94)

Aspirin is well tolerated but did not improve oxygen index or other physiological outcomes; a larger trial is not feasible in its current design.